Concomitant Intranasal Antihistamine and Corticosteroid in Stepwise Treatment Strategy for Allergic Rhinitis (INCS/INAH)

Gachon University Gil Medical Center

Status: Enrolling

Conditions: Allergic Rhinitis

Treatments: Drug: concomitant intranasal antihistamine and corticosteroid

Study type: Observational

Funder types: Other

Identifiers

NCT05708157

GCIRB2022-327

Details and patient eligibility

About

Patients with perennial allergic rhinitis whose symptoms are not controlled (visual analogue scale [VAS] ≥5) by 2-week treatment with intranasal corticosteroid will receive concomitant intranasal antihistamine and corticosteroid for 2 weeks. After 2-week treatment, changes in clinical parameters including VAS, total nasal symptom score (TNSS), total ocular symptom score (TOSS), rhinoconjunctivitis quality-of-life questionnaires (RQLQ) will be evaluated.

Full description

Patients with perennial allergic rhinitis whose symptoms are not controlled (visual analogue scale [VAS] ≥5) by 2-week treatment with intranasal corticosteroid will receive concomitant intranasal antihistamine and corticosteroid. In addition to VAS, total nasal symptom score (TNSS), total ocular symptom score (TOSS), rhinoconjunctivitis quality-of-life questionnaires (RQLQ) will be measured before treatment (baseline) and 2 week after treatment. The differences between parameters before treatment and those after 2-week treatment will be statistically analyzed using paired student t test, and p<0.05 was considered statistically significant.

Enrollment: 240 estimated patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Perinnial allergic rhinitis diagnosed by a doctor
• Positive for one or more of inhalant perinneal allergen in skin prick test or serum specific IgE measurement
• Age: 19 years or older
• Allergic rhinitis symptoms not controlled (VAS ≥5) by 2-week treatment with intranasal corticosteroid

Exclusion criteria

• Compliance for one or more drugs in last 2 weeks: <80%
• Use of oral corticosteroid, oral or intranasal decongestant in last 2 weeks
• Initiation of allergen-specific immunotherapy in last 12 months
• Seasonal allergic rhinitis
• Chronic rhinosinusitis other than allergic rhinitis
• Nasal polyposis
• Comorbid diseases including infectious, respiratory, cardiologic, renal, gastrointestinal, endocrinologic, oncologic, hemotologic and immunologic disorders which investigators judge to affect on the study significantly.
• Patients' rejection
• Pregenancy or lactation

Trial design

240 participants in 1 patient group

Active group

Description:

Patients with perennial allergic rhinitis who receive concomitant intranasal antihistamine and corticosteroid.

Treatment:

Drug: concomitant intranasal antihistamine and corticosteroid